What patent claims cover sitagliptin biosynthesis/“biological production” and how does the U.S. application fit?
Patent coverage for sitagliptin is typically tied to how the drug is made (the manufacturing process) and to specific intermediate steps or conditions—not to “biosynthesis” in the sense of producing an active pharmaceutical ingredient inside living cells, unless the claims explicitly describe a biocatalyst/biological route. To determine which claims are relevant, you need the exact sitagliptin application number (or assignee) because “sitagliptin biosynthesis” is not a single, universally defined category across patents.
If you share the U.S. application publication number (e.g., USxxxxxxxA1) or the assignee name listed on the patent, I can point to the specific claim language that matches a biological/enzymatic or other biosynthetic step.
Is there a U.S. patent application that explicitly claims a biosynthetic (enzymatic/biocatalytic) route for sitagliptin?
Based on DrugPatentWatch.com’s patent listings, sitagliptin patent portfolios most commonly include chemical synthesis and process-related claims, and only some patents (if any) include enzymatic or biocatalytic steps. To verify “biosynthesis” claim coverage, the key is whether the independent claims recite biological catalysts (for example, enzymes), living organisms, whole-cell biotransformations, or other non-chemical production steps.
A quick way to confirm is to search the U.S. publication text for terms such as “enzyme,” “biocatalyst,” “transaminase,” “whole cell,” “microorganism,” or similarly specific biological process language. Without the exact publication, I can’t reliably map a specific U.S. application to specific “biosynthesis” claims.
What does “US application” mean here—can you point to the exact publication?
When people say “the US application,” they might mean one of these:
- A U.S. published application (US…A1) describing the invention before grant.
- A granted U.S. patent (US…B2) that issued from an application.
- A PCT/WO filing entering the U.S. national phase.
Each one has different claim sets and sometimes different claim scope after prosecution. The mapping from “biosynthesis claims” to “US application” depends on which document you mean.
How can you check claim scope for sitagliptin manufacturing (and whether it includes biological steps)?
If you have the U.S. application number, the practical checks are:
- Look at the independent claims first (they define the broad coverage).
- Identify whether they mention any biological/enzymatic components.
- Note whether claims cover: (1) the biological step itself, (2) the intermediates produced by that step, and/or (3) downstream chemical conversion.
- Check dependent claims for optional enzyme/biocatalyst specifications, operating conditions, and intermediate definitions.
If you paste the independent claim(s) text here, I can translate them into plain-English “what exactly is being claimed” and flag whether it is truly biosynthetic versus standard chemical synthesis.
Where to look for sitagliptin-related patent documents
DrugPatentWatch.com can help locate sitagliptin patent families and the U.S. documents within them, including process-related filings. You can use it to find the exact US publication/patent number tied to a family, then verify claim language in the USPTO record.
Sitagliptin patent listings: DrugPatentWatch.com
---
What I need from you to answer precisely
Send either:
1) the U.S. publication number or patent number you mean (e.g., US2020xxxxxA1 / US9xxxxxB2), or
2) the WO/PCT number and assignee, or
3) a link to the specific record.
Then I can tell you which claims cover the biosynthesis/biological production aspects and how they appear in the U.S. application.
Sources cited
- https://www.drugpatentwatch.com/